| scholarly article | Q13442814 |
| P2093 | author name string | Pandolfi PP | |
| Warrell RP Jr | |||
| Calleja E | |||
| He LZ | |||
| Richon V | |||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| acute promyelocytic leukemia | Q612108 | ||
| P304 | page(s) | 1621-1625 | |
| P577 | publication date | 1998-11-01 | |
| P1433 | published in | Journal of the National Cancer Institute | Q400279 |
| P1476 | title | Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. | |
| P478 | volume | 90 |
| Q41736028 | A co-clinical platform to accelerate cancer treatment optimization. |
| Q57634693 | A conceptual framework for the identification of candidate drugs and drug targets in acute promyelocytic leukemia |
| Q44306437 | A fluorogenic histone deacetylase assay well suited for high-throughput activity screening |
| Q40307354 | A novel retinoic/butyric hyaluronan ester for the treatment of acute promyelocytic leukemia: preliminary preclinical results. |
| Q33619776 | A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas |
| Q40138108 | Aberrant association of promyelocytic leukemia protein-retinoic acid receptor-alpha with coactivators contributes to its ability to regulate gene expression |
| Q45111311 | Activity of the yeast Tat2p tryptophan permease is sensitive to the anti-tumor agent 4-phenylbutyrate |
| Q35205514 | Acute promyelocytic leukaemia in children |
| Q34926666 | Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia |
| Q31922432 | All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia |
| Q38055497 | All-trans retinoic acid in the treatment of pediatric acute promyelocytic leukemia. |
| Q45925779 | Alterations of epigenetics and microRNA in hepatocellular carcinoma. |
| Q40520464 | Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma |
| Q31922478 | Analysis of the molecular genetics of acute promyelocytic leukemia in mouse models |
| Q35677279 | Antagonism between granulocytic maturation and deacetylase inhibitor-induced apoptosis in acute promyelocytic leukaemia cells |
| Q29616624 | Anticancer activities of histone deacetylase inhibitors |
| Q43792226 | Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells |
| Q40840344 | Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells |
| Q38361778 | Arsenic trioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells |
| Q36546255 | Assays for pharmacodynamic analysis of histone deacetylase inhibitors |
| Q34435497 | Biological features of primary APL blasts: their relevance to the understanding of granulopoiesis, leukemogenesis and patient management |
| Q36085026 | Biology and management of relapsed acute myeloid leukaemia. |
| Q40294721 | CBHA is a family of hybrid polar compounds that inhibit histone deacetylase, and induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells |
| Q35551103 | Cancer epigenetics |
| Q44222428 | Cell division cycle control in embryonal and alveolar rhabdomyosarcomas |
| Q28828149 | Chemical chaperon 4-phenylbutyrate protects against the endoplasmic reticulum stress-mediated renal fibrosis in vivo and in vitro |
| Q35108777 | Chemoprevention of Tumors: The Role of RAR-Beta |
| Q34098840 | Chromatin modification and disease |
| Q34786248 | Chromatin modification, leukaemia and implications for therapy. |
| Q33703534 | Chromatin remodeling and transcriptional regulation |
| Q44433830 | Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug |
| Q34468570 | Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia |
| Q22253464 | Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor |
| Q24532118 | Cloning and characterization of a novel human histone deacetylase, HDAC8 |
| Q37725693 | Combined staurosporine and retinoic acid induces differentiation in retinoic acid resistant acute promyelocytic leukemia cell lines |
| Q78167223 | Complete remission in acute myeloid leukaemia with t(8;21) following treatment with G-CSF: flow cytometric analysis of in vivo and in vitro effects on cell maturation |
| Q94601791 | Concise Review: The Regulatory Mechanism of Lysine Acetylation in Mesenchymal Stem Cell Differentiation |
| Q34663691 | Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy |
| Q33279222 | Cytodifferentiation by retinoids, a novel therapeutic option in oncology: rational combinations with other therapeutic agents |
| Q33183127 | Cytodifferentiation: a novel approach to cancer treatment and prevention |
| Q34723825 | Designed transcription factors as structural, functional and therapeutic probes of chromatin in vivo. Fourth in review series on chromatin dynamics |
| Q79236564 | Diagnostic value of detecting fusion proteins derived from chromosome translocations in acute leukaemia |
| Q36179533 | Differential effects of histone deacetylase inhibitors in tumor and normal cells-what is the toxicological relevance? |
| Q34108096 | Differentiating agents in pediatric malignancies: all-trans-retinoic acid and arsenic in acute promyelocytic leukemia |
| Q74183810 | Differentiation induction as a treatment for hematologic malignancies |
| Q37206203 | Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha |
| Q36280490 | Dynamic and reversibility of heterochromatic gene silencing in human disease |
| Q24548340 | ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain |
| Q44606845 | Effect and comparison of sodium butyrate and trichostatin A on the proliferation/differentiation of K562. |
| Q31858549 | Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells |
| Q40358550 | Effects of sodium phenylbutyrate on differentiation and induction of the P21WAF1/CIP1 anti-oncogene in human liver carcinoma cell lines |
| Q35064126 | Emerging cancer-targeted therapies |
| Q36219655 | Emerging drugs for the treatment of myelodysplastic syndrome |
| Q40570608 | Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by phenylbutyrate on L1210 leukemic cells |
| Q89550961 | Epigenetic Control of a Local Chromatin Landscape |
| Q35551110 | Epigenetic targets in hematopoietic malignancies |
| Q37240566 | Epigenetics in acute myeloid leukemia |
| Q26823403 | Epigenomics of leukemia: from mechanisms to therapeutic applications |
| Q35093610 | Evidence of an Epigenetic Modification in Cell-cycle Arrest Caused by the Use of Ultra-highly-diluted Gonolobus Condurango Extract |
| Q40891228 | Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells |
| Q33349703 | Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation |
| Q34137347 | Future perspectives for acute promyelocytic leukemia therapy |
| Q34334826 | Genes, chromatin, and breast cancer: an epigenetic tale |
| Q34349653 | Genetic lesions and perturbation of chromatin architecture: a road to cell transformation |
| Q40529105 | Granulocytic differentiation of leukemic cells with t(9;11)(p22;q23) induced by all-trans-retinoic acid |
| Q80805979 | HDAC2 deficiency sensitizes colon cancer cells to TNFalpha-induced apoptosis through inhibition of NF-kappaB activity |
| Q24316497 | Hepatitis C virus NS5A as a potential viral Bcl-2 homologue interacts with Bax and inhibits apoptosis in hepatocellular carcinoma |
| Q40207567 | High-content fluorescence-based screening for epigenetic modulators |
| Q44619618 | Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice |
| Q60195653 | Histone Deacetylase Inhibitor (HDACi) Conjugated Polycaprolactone for Combination Cancer Therapy |
| Q55952250 | Histone Deacetylase Inhibitors |
| Q34956099 | Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation |
| Q34488424 | Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. |
| Q34336927 | Histone deacetylase as a therapeutic target |
| Q40501526 | Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo |
| Q39545404 | Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells |
| Q45250335 | Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid |
| Q33568495 | Histone deacetylase inhibitor therapy in epithelial ovarian cancer |
| Q80489191 | Histone deacetylase inhibitors |
| Q50507906 | Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. |
| Q40450785 | Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. |
| Q57272462 | Histone deacetylase inhibitors in cancer therapy |
| Q43831725 | Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression |
| Q43795700 | Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17). |
| Q24671020 | Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia |
| Q40536301 | Histone deacetylase inhibitors regulate p21WAF1 gene expression at the post-transcriptional level in HepG2 cells |
| Q35011880 | Histone deacetylase inhibitors: from target to clinical trials |
| Q28142463 | Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells |
| Q34119504 | Histone deacetylase inhibitors: novel anticancer agents |
| Q37821337 | Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect |
| Q24535587 | Histone deacetylases (HDACs): characterization of the classical HDAC family |
| Q34570082 | Histone deacetylases and cancer: causes and therapies |
| Q26777453 | Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer |
| Q34290298 | Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? |
| Q34322087 | Histone modification enzymes: novel targets for cancer drugs |
| Q34743301 | Histone-deacetylase inhibitors: novel drugs for the treatment of cancer |
| Q40334140 | Immunohistochemical analysis of acetylation, proliferation, mitosis, and apoptosis in tumor xenografts following administration of a histone deacetylase inhibitor--a pilot study |
| Q33185196 | In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia |
| Q34405484 | In vivo analysis of the molecular genetics of acute promyelocytic leukemia |
| Q33739259 | In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications |
| Q40803071 | In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD / Shi-scid/scid mice. |
| Q36108372 | Inducible covalent posttranslational modification of histone H3. |
| Q30310695 | Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway |
| Q39602340 | Inhibition of histone deacetylation induces constitutive derepression of the beta interferon promoter and confers antiviral activity |
| Q34608747 | Inhibition of the NAD-dependent protein deacetylase SIRT2 induces granulocytic differentiation in human leukemia cells. |
| Q74183402 | Inhibitory effect of 1-O (2 methoxy) hexadecyl glycerol and phenylbutyrate on the malignant properties of human prostate cancer cells |
| Q44326399 | Interleukin-1beta converting enzyme subfamily inhibitors prevent induction of CD86 molecules by butyrate through a CREB-dependent mechanism in HL60 cells |
| Q35909283 | Investigational agents in myeloid disorders |
| Q34275371 | Leukaemogenesis: more than mutant genes |
| Q34079213 | Location and function of critical genes in leukemogenesis inferred from cytogenetic abnormalities in hematologic malignancies |
| Q40355783 | M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells |
| Q34055317 | Mechanisms of all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells |
| Q37437996 | Metastasis-associated gene 1 promotes invasion and migration potential of laryngeal squamous cell carcinoma cells |
| Q35537914 | Modified fatty acids and their possible therapeutic targets in malignant diseases |
| Q34091001 | Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors |
| Q37240767 | Modulation of histone deacetylase activity by dietary isothiocyanates and allyl sulfides: studies with sulforaphane and garlic organosulfur compounds |
| Q33633027 | Molecular genetics of acute promyelocytic leukemia. |
| Q34499630 | Molecular modeling study on tunnel behavior in different histone deacetylase isoforms |
| Q35782919 | Molecular therapeutic approaches to acute myeloid leukemia: targeting aberrant chromatin dynamics and signal transduction. |
| Q35190696 | Monitoring PML-RARalpha in acute promyelocytic leukemia |
| Q39609451 | N-myc downstream-regulated gene 1 (NDRG1) a differentiation marker of human breast cancer |
| Q34996318 | New advances in the treatment of acute promyelocytic leukemia |
| Q35639964 | New agents in acute myeloid leukemia and other myeloid disorders |
| Q34678359 | New drugs in gynecologic cancer |
| Q40417508 | New method to detect histone acetylation levels by flow cytometry |
| Q34380256 | New perspectives of valproic acid in clinical practice. |
| Q73614690 | Nonisotopic substrate for assaying both human zinc and NAD+-dependent histone deacetylases |
| Q34043331 | Novel strategies and therapeutics for the treatment of prostate carcinoma |
| Q35684127 | Novel treatments in non-small cell lung cancer |
| Q24610640 | Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway |
| Q24550754 | Oligomerization of ETO is obligatory for corepressor interaction |
| Q27023342 | One mouse, one patient paradigm: New avatars of personalized cancer therapy |
| Q46713722 | Opinion: how patients have benefited from mouse models of acute promyelocytic leukaemia |
| Q35800437 | Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study |
| Q33765339 | Organization of chromatin in cancer cells: role of signalling pathways |
| Q36967849 | PML-RARalpha inhibitors (ATRA, tamibaroten, arsenic troxide) for acute promyelocytic leukemia |
| Q34435558 | Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission |
| Q43269070 | Peroxisome proliferator-activated receptor gamma agonists potentiate the cytotoxic effect of valproic acid in multiple myeloma cells |
| Q33741025 | Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome |
| Q40277377 | Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors |
| Q36321611 | Phenylbutyrate up-regulates the adrenoleukodystrophy-related gene as a nonclassical peroxisome proliferator |
| Q28305184 | Phosphorylation of Ser28 in histone H3 mediated by mixed lineage kinase-like mitogen-activated protein triple kinase alpha |
| Q46853686 | Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. |
| Q44349057 | Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells |
| Q33651762 | Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer |
| Q46611130 | Prolonged molecular remission in PML-RARalpha-positive acute promyelocytic leukemia treated with minimal chemotherapy followed by maintenance including the histone deacetylase inhibitor sodium valproate |
| Q33846392 | Promyelocytic leukemia zinc finger-retinoic acid receptor α (PLZF-RARα), an oncogenic transcriptional repressor of cyclin-dependent kinase inhibitor 1A (p21WAF/CDKN1A) and tumor protein p53 (TP53) genes |
| Q36956230 | RAR and RXR modulation in cancer and metabolic disease |
| Q40080615 | RNA interference of metastasis-associated gene 1 inhibits metastasis of B16F10 melanoma cells in a C57BL/6 mouse model |
| Q35067608 | RUNX1 regulates corepressor interactions of PU.1. |
| Q44874861 | Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1. |
| Q35563857 | Recent progress in the development of assays suited for histone deacetylase inhibitor screening |
| Q40279441 | Reduced MTA1 expression by RNAi inhibits in vitro invasion and migration of esophageal squamous cell carcinoma cell line |
| Q40601604 | Regulation of cell growth and expression of 7B2, PC2, and PC1/3 by TGFbeta 1 and sodium butyrate in a human pituitary cell line (HP75). |
| Q39411673 | Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer |
| Q34926648 | Retinoic acid resistance in acute promyelocytic leukemia |
| Q38331050 | Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo. |
| Q33954693 | Retinoids in chemoprevention and differentiation therapy |
| Q34334833 | Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer |
| Q33862993 | Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation |
| Q33652165 | Runx1 regulation of Pu.1 corepressor/coactivator exchange identifies specific molecular targets for leukemia differentiation therapy. |
| Q36571944 | SRC proximal and core promoter elements dictate TAF1 dependence and transcriptional repression by histone deacetylase inhibitors |
| Q34431562 | Searching for the magic bullet against cancer: the butyrate saga |
| Q33783545 | Short-chain fatty acids enhance nuclear receptor activity through mitogen-activated protein kinase activation and histone deacetylase inhibition. |
| Q44353897 | Sp family of transcription factors is involved in valproic acid-induced expression of Galphai2. |
| Q51088788 | Structural Requirements of HDAC Inhibitors: SAHA Analogues Modified at the C2 Position Display HDAC6/8 Selectivity. |
| Q37397791 | Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. |
| Q34074884 | Targeted therapies for the myeloid leukaemias |
| Q35568084 | The APL paradigm and the "co-clinical trial" project |
| Q33665836 | The PML nuclear bodies: actors or extras? |
| Q34548159 | The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia |
| Q34214835 | The biology of acute promyelocytic leukemia |
| Q34837015 | The emergence of resistance to targeted cancer therapeutics |
| Q35160462 | The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2 |
| Q28216000 | The leukaemia-associated transcription factors EVI-1 and MDS1/EVI1 repress transcription and interact with histone deacetylase |
| Q35087052 | The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease |
| Q33723609 | The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease |
| Q34570078 | The promise of retinoids to fight against cancer. |
| Q37841146 | The role of HDACs inhibitors in childhood and adolescence acute leukemias |
| Q47390566 | The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity. |
| Q34173877 | Transcription factors and translocations in lymphoid and myeloid leukemia |
| Q34290301 | Transcription therapy for cancer |
| Q34435531 | Transcriptional regulation in acute promyelocytic leukemia. |
| Q73977234 | Transcriptional regulation of cellular transformation |
| Q34435522 | Translocations of the RARalpha gene in acute promyelocytic leukemia |
| Q35186873 | Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate |
| Q35205528 | Treatment options for relapsed acute promyelocytic leukaemia |
| Q27000542 | Trials with 'epigenetic' drugs: an update |
| Q43696024 | Tributyrin, an oral butyrate analogue, induces apoptosis through the activation of caspase-3. |
| Q44555704 | Trichostatin A induces differential cell cycle arrests but does not induce apoptosis in primary cultures of mitogen-stimulated rat hepatocytes |
| Q44207181 | Trifluoromethyl ketones as inhibitors of histone deacetylase |
| Q40381466 | Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells |
| Q37137493 | Upregulation of p21Waf1/Cip1 expression in vivo by butyrate administration can be chemoprotective or chemopromotive depending on the lipid component of the diet |
| Q28366303 | Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells |
| Q34254302 | Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL. |
Search more.